Les aberrations chromosomiques observées dans les cellules sanguines humaines irradiées in vitro avec des flux différents d'electrons rapides (35 MeV). Implications radiothérapiques eventuelles

Human blood cells harvested in vitro were irradiated at the 55th hour with 35MeV electrons. Five samples of cultures received 200 r at different dose rates of respectively 10, 50, 100, 250 and 450 r/min; 5 other samples were irradiated in the same conditions with 400 r. One hit chromosomial aberrations were not dose rate dependent whereas 2 hit aberrations were related to dose rate. © 1967.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Hématologie générale

1re édition 1998-1999/12e Doctorat Médecineinfo:eu-repo/semantics/published

Étude des aberrations chromosomiques provoquées par la bleomycine sur les lymphocytes humains in vitro

The authors tried to determine a dose effect relation between the concentration of bleomycin and the number of chromosomal aberrations 'in vitro' in human lymphocytes during 48 hr cultures. Concentrations of 1 γ/ml, 2 γ/ml, 10 γ/ml and 20 γ/ml were used. The number of normal cells seems to decrease according to an exponential function; at a concentration of 20 γ/ml, 15% of the cells were apparently normal and this raises the problem of chemotherapeutic agent resistance. The number of one hit and 2 hit damages increases according to the dose of bleomycin but it was not possible to determine a mathematical relation of the phenomenon. Like viruses and other chemicals, bleomycin was responsible for 'pulverization' of chromosomes in several cells.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

Fanconi's anaemia. Simultaneous onset in 2 siblings and unusual cytological findings

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.

Case ReportsLetterSCOPUS: le.jinfo:eu-repo/semantics/publishe

Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

The short-term beneficial effect of hydroxyurea (HU) in sickle cell disease (SCD) has been proven by randomized studies in children and adults. The Belgian registry of HU-treated SCD patients was created to evaluate its long-term efficacy and toxicity. The median follow-up of the 93 patients registered is 3.5 years; clinical and laboratory data have been obtained for 82 patients at 1 year, 61 at 2 years, 44 at 3 years, 33 at 4 years, and 22 after 5 years. On HU, the number of hospitalizations and days hospitalized dropped significantly. Analysis of the 22 patients with a minimum of 5 years of follow-up confirm a significant difference in the number of hospitalizations (P =.0002) and days in the hospital (P <.01), throughout the treatment when compared to prior to HU therapy. The probabilities of not experiencing any event or any vaso-occlusive crisis requiring hospitalization during the 5 years of treatment were, respectively, 47% and 55%. On HU, the rate per 100 patient-years of severe events was estimated to be 3.5% for acute chest syndrome, 1.2% for aplastic crisis, 0.4% for splenic sequestration; it was 0% for the 9 patients with a history of stroke or transient ischemic attack followed for an average of 4 years. No important adverse effect occurred. Long-term chronic treatment with HU for patients with SCD appears feasible, effective, and devoid of any major toxicity; in patients with a history of stroke, HU may be a valid alternative to chronic transfusion support. (Blood. 2001;97:3628-3632)Journal ArticleResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe